The Latest Breaking News from BMY

Recession odds are rising due to the onslaught of aggressive rate hikes by the Fed. Healthcare is conventionally considered a defensive sector. Hence, we think Johnson & Johnson (JNJ), AbbVie (ABBV), and Bristol-Myers Squibb (BMY) might be solid buys now. Read on….

Blood thinners produced by drug giants Bristol Myers and Bayer fell short of predictions, leading shares of both stocks down Monday.

The U.S. market came back in July and early August owing to a robust job market, strong corporate earnings, and a slight decline in inflation. However, the Fed’s hawkish stance to hike the interest rates aggressively until inflation comes down to the target level is expected to keep the market…

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Substantial investments in R&D, an aging population, and growing demand for advanced drugs to treat chronic diseases should drive the pharmaceutical industry’s growth. Therefore, investing in fundamentally strong and dividend-paying pharma stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) could help dodge the current market volatility and generate substantial…

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The stock market has witnessed a rough ride amid macroeconomic headwinds this year. Despite the GDP decline for two consecutive quarters, economists believe the economy is far from recession. Here are five fundamentally solid value stocks AstroNova (ALOT), Bristol-Myers Squibb (BMY), Bluegreen Vacations (BVH), GSK (GSK), and Honda Motor (HMC),…

With the Fed committed to its rate hikes to bring down inflation, employment staggering, and prices refusing to come down, stagflation might be around the corner. We believe these high-yield dividend stocks Natural Resource(NRP), Kronos Worldwide(KRO), and Bristol-Myers Squibb(BMY) might help one beat the stagflation. Read more….

Bristol Myers Squibb expects a $10 billion or double-digit decline from its generics-facing products. BMY stock fell Wednesday.

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.